年轻及中年成人主动脉瓣置换:TAVR的当前与潜在作用
基于STS国家数据库2013至2018年数据,分析18至55岁成人主动脉瓣置换的实践模式与结局。共纳入1580例CHSD和44173例ACSD手术,TAVR使用率1%但增长167%。SAVR结果优异,卒中率低于孤立TAVR,数据支持该人群优选SAVR,但需前瞻性试验。
要点
- 年轻及中年成人主动脉瓣置换中,机械瓣占42%、生物瓣占55%、TAVR仅1%但增长167%。
- 多变量分析显示机械瓣死亡风险更低,TAVR先天 morbidity 风险更高且住院时间更短。
核心结论
- 尽管TAVR在55岁以下成人中应用增加,但SAVR死亡率和发病率结果优异,尤其卒中方面,数据支持该人群优选SAVR,需前瞻性试验验证。
研究设计与样本
- 回顾性分析STS国家数据库(CHSD和ACSD)中2013至2018年18至55岁接受SAVR或TAVR的成人,共1580例CHSD和44173例ACSD手术。
主要发现
- 瓣膜使用分布:TAVR 1%、机械瓣42%、生物瓣55%、自体移植0.6%、同种瓣1.2%、Ozaki 0.4%。
- TAVR体积随时间增加167%。
- 30天死亡率:TAVR 3.8%、机械瓣3.2%、生物瓣3.7%、自体移植0.6%、同种瓣9%、Ozaki 3.4%。
- 多变量分析:机械瓣死亡风险更低,TAVR先天 morbidity 风险更高,TAVR住院时间更短。
临床怎么用
- 对于18至55岁主动脉瓣疾病患者,SAVR尤其是机械瓣可能提供更优的死亡率和卒中结局,TAVR应谨慎选择。
局限性
- 研究为回顾性数据库分析,非随机对照,可能存在选择偏倚和未测量混杂因素,需前瞻性试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contemporary practice patterns and outcomes for aortic valve replacement (AVR) among young and middle-aged adults are unknown given guideline modifications for surgical AVR (SAVR) and increasing transcatheter AVR (TAVR) acceptance. This study describes SAVR and TAVR use and outcomes using The Society of Thoracic Surgeons (STS) National Databases. METHODS: Adults 18 to 55 years of age in the Congenital Heart Surgery Database (CHSD) and the Adult Cardiac Surgery Database (ACSD) who underwent SAVR or TAVR from 2013 to 2018 were included. Perioperative characteristics and early outcomes were described by valve type. Multivariable regression identified determinants of death, length of hospital stay, and a composite end point of renal failure, persistent neurologic deficit, readmission, and reoperation. RESULTS: The study analyzed 1580 unique CHSD and 44,173 ACSD operations, 16% of which were performed in patients with congenital heart disease. Valve use included the following: TAVR, 1%; mechanical, 42%; bioprosthetic, 55%; autograft, 0.6%; homograft, 1.2%; and Ozaki, 0.4%. Over time, TAVR volumes increased by 167%. The 30-day mortality was as follows: TAVR, 3.8%; mechanical, 3.2%; bioprosthetic, 3.7%; autograft, 0.6%; homograft, 9%; and Ozaki, 3.4%. Stroke rate was lower for isolated SAVR vs isolated TAVR (0.9% vs 2.4%; P = .002). In multivariable analyses, mortality risk was lower with mechanical valves, congenital morbidity risk was higher with TAVR, and length of stay was shorter with TAVR. CONCLUSIONS: TAVR is increasingly used for adults younger than 55 years of age. Given the uniformly excellent results with SAVR, including both mortality and morbidity-particularly regarding stroke, our data favor SAVR in this population, but a prospective trial is needed. Ongoing efforts to harmonize variables and outcomes definitions between the ACSD and CHSD are valuable.
引用
- Nelson JS, Maul TM, Wearden PD, et al. Aortic Valve Replacement in Young and Middle-Aged Adults: Current and Potential Roles of TAVR. Ann Thorac Surg. 2020. PMID: 32768428. doi:10.1016/j.athoracsur.2020.05.180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。